HCWB NASDAQ
Miramar, FL 33025
US
HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Wong Hing C | P-Purchase | 8,054 | $7.45 | 2025-05-16 |
| Winer Gary M | P-Purchase | 1,342 | $7.45 | 2025-05-16 |
| GARRETT SCOTT T | P-Purchase | 13,423 | $7.45 | 2025-05-16 |
| Winer Gary M | P-Purchase | 2,308 | $26.00 | 2025-05-08 |
| Wong Hing C | P-Purchase | 92,500 | $26.00 | 2025-05-08 |